Targeting KRAS mutant lung cancer: light at the end of the tunnel
Matthias Drosten1, Mariano Barbacid1
1Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Abstract:
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12C inhibitors represents a landmark after 40 years of intense research efforts since the identification of KRAS as a human oncogene. Here, we discuss the mechanisms responsible for the rapid development of resistance to these inhibitors, as well as potential strategies to overcome this limitation. Other therapeutic strategies aimed at inhibiting KRAS oncogenic signaling by targeting either upstream activators or downstream effectors are also reviewed. Finally, we discuss the effect of targeting the mitogen-activated protein kinase (MAPK) pathway, both based on the failure of MEK and ERK inhibitors in clinical trials, as well as on the recent identification of RAF1 as a potential target due to its MAPK-independent activity. These new developments, taken together, are likely to open new avenues to effectively treat KRAS mutant LUAD.
Insights
Targeting KRAS G12C in lung adenocarcinoma shows promise, but resistance mechanisms require new strategies. Research explores overcoming resistance and alternative pathways like RAF1 to improve KRAS mutant LUAD treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS-mutant lung adenocarcinomas (LUAD) are challenging to treat with personalized medicine.
- Selective KRAS G12C inhibitors offer a breakthrough after 40 years of research.
- Developing targeted therapies with acceptable toxicity remains complex.
Purpose of the Study:
- To review mechanisms of resistance to KRAS G12C inhibitors in LUAD.
- To discuss strategies for overcoming acquired resistance.
- To explore alternative therapeutic approaches for KRAS-mutant LUAD.
Main Methods:
- Review of recent literature on KRAS G12C inhibitors and resistance mechanisms.
- Analysis of therapeutic strategies targeting upstream activators and downstream effectors of KRAS.
- Evaluation of the role of the MAPK pathway and potential targets like RAF1.
Main Results:
- KRAS G12C inhibitors represent a significant advancement in LUAD treatment.
- Rapid resistance development is a key challenge.
- Targeting RAF1 offers a potential MAPK-independent therapeutic avenue.
Conclusions:
- Understanding resistance mechanisms is crucial for effective KRAS-targeted therapy.
- Combination strategies and novel targets like RAF1 may improve outcomes for KRAS-mutant LUAD.
- Further research is needed to translate these findings into clinical practice.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38The Ras Gene
Ras is a...
02:23Abnormal Proliferation